METHODS: Fourteen survey questions assessing current attitudes toward digital cytology were developed from a 2016 ASC Digital Pathology Survey. Ten new survey questions were also created to evaluate telecytology use. The survey was e-mailed to ASC members over 6 weeks in 2023.
RESULTS: A total of 123 individuals responded (116 in 2016). Attitudes toward digital cytology were unchanged; most participants stated digital cytology is beneficial (87% 2023 versus 90% 2016). The percentage of individuals using digital cytology was unchanged (56% in 2016 and 2023). However, telecytology for rapid onsite assessment (ROSE) is now considered the best application (55% 2023 versus 31% 2016). Forty-three institutions reported using digital and telecytology tools; 40% made implementations after 2020; most did not feel that COVID-19 affected digital cytology (56%). Telecytology for ROSE is the most common application now (78%) compared with education (30%) in 2016. Limitations for implementing digital imaging in cytology included inability to focus (38%) and expense (33%).
CONCLUSIONS: General attitudes toward digital tools by the cytology community have essentially remained the same between 2016 and now. However, telecytology for ROSE is increasingly being used, which supports a need for validation and competency guidelines.
方法:评估当前对数字细胞学态度的十四个调查问题来自2016年ASC数字病理学调查。还创建了十个新的调查问题来评估电信使用情况。该调查在2023年的6周内通过电子邮件发送给ASC成员。
结果:共有123人做出回应(2016年为116人)。对数字细胞学的态度没有改变;大多数参与者表示数字细胞学是有益的(2023年为87%,2016年为90%)。使用数字细胞学的个人比例没有变化(2016年和2023年为56%)。然而,远程快速现场评估(ROSE)现在被认为是最佳应用(2023年为55%,2016年为31%)。43个机构报告使用数字和电信工具;40%在2020年后实施;大多数人认为COVID-19没有影响数字细胞学(56%)。与2016年的教育(30%)相比,ROSE的远程学习是现在最常见的应用(78%)。在细胞学中实施数字成像的局限性包括无法聚焦(38%)和费用(33%)。
结论:从2016年到现在,细胞学界对数字工具的总体态度基本保持不变。然而,ROSE的电信学越来越多地被使用,这支持对验证和能力准则的需求。